Allele Symbol Allele Name Allele ID |
Pdgfrbtm11Sor targeted mutation 11, Philippe Soriano MGI:3526812 |
||||||||||||||||
Summary |
3 genotypes
|
|
|
♀ | phenotype observed in females |
♂ | phenotype observed in males |
N | normal phenotype |
|
|
♀ | phenotype observed in females |
♂ | phenotype observed in males |
N | normal phenotype |
• few mutants are recovered after birth, however mutants are recovered at E18.5, indicating perinatal lethality
|
|
• testes are frequently hemorrhagic at E18.5
|
• reduction in steroid-producing cells in the adrenal glands at E18.5
|
• reduction in adrenal cortex
|
• small adrenal glands are seen just before birth (E18.5)
|
|
• reduction in steroid-producing cells in the testis at E18.5
|
|
• small testes at E18.5
|
|
• testes are frequently hemorrhagic at E18.5
|
|
• testes are frequently hemorrhagic at E18.5
|
|
• reduction in steroid-producing cells in the testis at E18.5
|
|
• small testes at E18.5
|
|
|
♀ | phenotype observed in females |
♂ | phenotype observed in males |
N | normal phenotype |
N |
• at 3 months of age, all mutants have normal visual acuity
• no retinal pathology is evident and vitreous is clear
• normal vision is in contrast to Cdnk2a compound heterozygotes not carrying the floxed Pdgfr allele which show significantly compromised visual acuity
|
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO) |
||
Citing These Resources Funding Information Warranty Disclaimer, Privacy Notice, Licensing, & Copyright Send questions and comments to User Support. |
last database update 08/02/2024 MGI 6.24 |
![]() |
|